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documented the comparability of results between CAS and
surgical management for restensosis after primary CEA.
However, in the absence of randomized clinical trial proce-
dures,5 we are currently unwilling to expand the use of CAS
beyond these defined subgroups of patients.11
An additional concern about the CAS procedure has
been the potential for development of in-stent resteno-
sis.12,13 This complication has been observed after coronary
stenting in 16% to 59% of cases,14-16 whereas in-stent
restenosis after iliac stenting has been observed in 13% to
39% of reported series.17-19 In-stent restenosis after CAS has
been reported in only 4% to 5% of cases (Table I)3,4,20,21;
however, clinical follow-up has been relatively short, gener-
ally less than 12 months. The purpose of the current study is
to determine the incidence of in-stent restenosis after CAS in
our clinical series and to evaluate the utility of endovascular
techniques for the management of in-stent restenosis.
METHODS
Patient population. Between September 1996 and
May 2000, 50 CAS procedures were performed on 46
consecutive patients according to a protocol approved by
the Institutional Review Board to investigate the feasibil-
ity of CAS. Twenty-six patients were men (57%), and 20
were women (43%) with a mean age of 69 ± 11 years.
Symptomatic and asymptomatic high-grade stenoses 
(≥ 80%) were included in this protocol. Baseline clinical
characteristics of the group are summarized in Table II.
Of the 50 stenotic lesions, 40 (80%) were post-CEA
restenoses, 9 (18%) were primary lesions in patients with
critical two- or three-vessel coronary artery disease, and 1
Carotid angioplasty-stenting (CAS) has been recom-
mended by some clinicians as an alternative to carotid
endarterectomy (CEA).1-4 However, as emphasized in the
recent consensus statement from the American Heart
Association,5 this new catheter-based procedure should be
restricted to limited subgroups of patients, whereas the gold
standard of endarterectomy remains the preferred method
for the management of most patients with carotid occlusive
disease. CEA has emerged as the optimal treatment for
symptomatic and asymptomatic patients with high-grade
extracranial carotid stenoses.6-10 However, according to the
conclusions of a multidisciplinary panel at the recent
Montefiore Vascular Symposium,11 subgroups of patients
including high-risk patients with significant medical comor-
bidities, those with carotid restenosis after prior CEA, those
with anatomically inaccessible lesions above the second rib,
and those with radiation-induced stenoses should currently
be considered for CAS. As an example, our group12 recently
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Purpose: Carotid angioplasty-stenting (CAS) has been advocated as an alternative to carotid endarterectomy (CEA) in
patients with restenotic lesions after prior CEA, primary stenoses with significant medical comorbidities, and radiation-
induced stenoses. The incidence of restenosis after CAS and its management remains ill defined. We evaluated the inci-
dence and management of in-stent restenosis after CAS. 
Methods: Patients with asymptomatic (61%) and symptomatic (39%) carotid stenosis of ≥ 80% underwent CAS between
September 1996 and May 2000; there were 50 procedures and 46 patients (26 men and 20 women). All patients were
followed up clinically and underwent duplex ultrasonography (DU) at 3- to 6-month intervals. In-stent restenoses
≥ 80% detected with DU were further evaluated by means of angiography for confirmation of the severity of stenosis. 
Results: No periprocedural or late strokes occurred in the 50 CAS procedures during the 30-day follow-up period. One
death (2.2%) that resulted from myocardial infarction was observed 10 days after discharge following CAS. During a
mean follow-up period of 18 ± 10 months (range, 1-44 months), in-stent restenosis was observed after four (8%) of
the 50 CAS procedures. Angiography confirmed these high-grade (≥ 80%) in-stent restenoses, which were successfully
treated with balloon angioplasty (3) or angioplasty and restenting (1). No periprocedural complications occurred, and
these patients remained asymptomatic and without recurrent restenosis over a mean follow-up time of 10 ± 6 months. 
Conclusions: We recommend CAS for post-CEA restenosis, primary stenoses in patients with high-risk medical comor-
bidities, and radiation-induced stenoses. In-stent restenoses occurred after 8% of CAS procedures and were managed
without complications with repeat angioplasty or repeat angioplasty and restenting. (J Vasc Surg 2001;33:220-6.)
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(2%) was a stenosis that was complicating childhood cer-
vical radiation therapy.
Clinical protocol and follow-up. Clinical, angio-
graphic, and procedural data were prospectively collected.
Prior to and 24 hours after CAS, patients were examined by
the vascular surgeon, interventionist, or, in some instances,
an independent neurologist. All patients were followed up
prospectively at 3- to 6-month intervals clinically and
underwent duplex ultrasonography (DU). Restenotic
lesions detected with DU were further evaluated with
angiography for confirmation of the severity of stenosis.
CAS protocol. CAS was performed as previously
described12 (Fig 1). Patients were pretreated with aspirin
(325 mg/d) for at least 2 days before the procedure and
with either ticlopidine (250 mg twice daily) or clopidogrel
(75 mg once daily) after a loading dose that was given the
day of the procedure. Aspirin and one of the other two
antiplatelet agents were continued for 4 weeks after CAS
with aspirin therapy alone thereafter. Patients received
intravenous sedation, and local anesthesia was achieved
with infiltration of 1% lidocaine (Xylocaine). Venous access
was secured in all patients, and a transvenous pacemaker
was routinely available. Standard retrograde access was per-
formed in the common femoral artery, and a 6F vascular
sheath was inserted. Weight-adjusted heparin was adminis-
tered (70 U/kg), and the activated clotting time was main-
tained at 225 to 250 seconds throughout the procedure. A
0.035-in guidewire (Wholey modified J, 175-cm;
Mallinkrodt, St Louis, MO,) in a 5F Vitek or HN2 cere-
bral diagnostic catheter (Cook, Bloomington, Ind) was
introduced for selective cannulation of the common
carotid artery (CCA). Digital angiography was performed
to confirm the severity of stenosis. Subsequently, the diag-
nostic catheter was exchanged over a 0.035-in exchange-
length (260 cm) Amplatz Super Stiff guidewire
(Meditech/Boston Scientific, Natick, Mass) for an 8F 100-
cm long sheath that was passed into the CCA. The steno-
sis was crossed with a 0.018-in Roadrunner extrasupport
guidewire (Cook), and prestent dilatation was performed
with low-profile 4 × 30-mm balloon catheters inflated to 8
atm, followed by stent deployment. Poststent dilatation
was performed with 5- or 6-mm high-pressure balloons
inflated to 12 atm. In the 46 patients, 50 stents were used
during the carotid interventions. One patient underwent
staged bilateral CAS procedures with Wallstents for post-
CEA restenoses, and three patients had use of a second
stent (2 Wallstents and 1 Palmaz stent) for separate
stenoses in the CCA. Of the 50 stents, 49 (98%) were self-
expanding Wallstents, 8 × 20 mm and 10 × 20 mm
(Meditech/Boston Scientific, Minneapolis, Minn), and 1
(2%) was a Palmaz P-154 stent (Johnson and Johnson
Interventional Systems Co, Warren, NJ). On completion
of the procedure, ipsilateral carotid and intracranial angiog-
raphy was performed to assess technical success and to
exclude distal cerebral embolization. Vascular sheaths were
removed after the procedure, and femoral hemostasis was
accomplished by means of a transcatheter closure device,
Prostar XL (Perclose/Abbott, Redwood City, Calif).
Imaging criteria and end points. Restenosis
detected with DU was classified as moderate (50%-79%)
and severe (≥ 80%).
Quantitative angiographic analysis was performed on
all arteries before and after CAS and for verification of
restenosis detected with follow-up DU. An on-line soft-
ware program of quantitative angiographic analysis was
used (MDQM; MEDCON Telemedicine Technology,
Inc, Livingston, NJ). With criteria from the North
American Symptomatic Carotid Endarterectomy Trial,6
the degree of stenosis was determined by comparison of
the least transverse diameter at the maximal stenosis with
the reference diameter of the distal internal carotid artery
once its walls became parallel. The minimal lumen diame-
ter was measured after calibration of the system with the
known diameter of the guiding catheter. Patients with
high-grade restenosis (> 80%) revealed by DU underwent
confirmatory angiography before reinterventions.
RESULTS
Demographics and outcome. CAS was performed on
50 carotid stenoses in 46 patients (Table II). There were
26 men (57%) and 20 women (43%). Of the 46 patients,
28 were asymptomatic (61%) and 18 were symptomatic
(39%). Of the symptomatic group, six patients had hemi-
spheric transient ischemic attacks (TIAs) without neuro-
logic deficits, and two patients had amaurosis fugax. The
remaining 10 patients complained of global symptoms,
including severe lightheadedness, syncopal episodes, or
both, but without any lateralizing neurologic deficits.
After CAS, all patients were followed up clinically and
Table II. Baseline clinical characteristics of the study
group (N = 46)
n %
Men 26 57
Women 20 43
Asymptomatic (> 80%) 28 61
Symptomatic 18 39
Hemispheric TIA 6 13
Amaurosis fugax 2 4
Global symptoms 10 22
Diabetes 15 33
Hypertension 39 85
Smoker 23 50
Hypercholesterolemia 23 50
Coronary artery disease 25 54
Table I. Incidence of in-stent restenosis after CAS
n Restenosis (%) Follow-up (mo)
Diethrich et al3 110 4.5 8
Theron20 93 4. 12
Yadav et al4 126 4.9 6
Wholey et al21 2048 4.8 6
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underwent DU at 3- to 6-month intervals during a
mean follow-up time of 18 ± 10 months (range, 1-44
months). No minor or major strokes were observed in
this series of 50 CAS procedures. Two TIAs were
observed during CAS. Each resolved spontaneously
within minutes of its onset and without residual deficits.
One patient (2.2%) died in this series. This 72-year-old
woman had undergone a two-vessel coronary angio-
Fig 1. A, Selective angiography in symptomatic patient presenting with single episode of amaurosis fugax 11 months after prior right
CEA, demonstrating focal high-grade restenosis (arrow). B, Poststent deployment angioplasty resulted in technically satisfactory angio-
graphic results (arrows refer to length of stent). C, In-stent restenosis was defined angiographically in two areas (arrows) in this patient
6 months after CAS. D, Angioplasties of both areas reduced lesions to < 30% residual stenoses (arrows), which have not recurred dur-
ing a 14-month follow-up.
A
C
B
D
JOURNAL OF VASCULAR SURGERY
Volume 33, Number 2 Chakhtoura et al 223
plasty with stenting 2 days before CAS. Ten days after
her discharge from the hospital, she died suddenly, pre-
sumably as a result of myocardial infarction. All other
patients have remained asymptomatic.
In-stent restenosis. Six in-stent restenoses were
observed on follow-up DU: two (4%) were classified as
moderate (50%-79%), and four (8%) were severe (> 80%).
After evaluation with angiography, the two moderate
stenoses were found to have < 50% stenosis and were not
treated. The high-grade stenoses (> 80%) were confirmed
in the other four patients, thus meeting the criterion for
reintervention. Three of the treated in-stent restenoses
developed in patients after CAS for post-CEA restenosis,
whereas the fourth restenosis developed after an initial
CAS procedure for radiation-induced stenosis. The clini-
cal characteristics of patients with in-stent restenosis are
outlined in Table III. Although these patients were
asymptomatic, reintervention was recommended because
of the severity of their restenosis (≥ 80%) and the presence
of accompanying contralateral occlusion. In-stent
restenosis was observed at a mean interval of 13 ± 7
months (range, 6-21 months) after the original CAS pro-
cedure. Three of the four restenoses were treated with
angioplasty alone (Fig 2). The remaining patient was
treated with angioplasty and restenting with a Palmaz
stent. All four patients remained asymptomatic and with-
out recurrent restenosis over a mean follow-up time of 10
± 6 months (range, 1-14 months).
DISCUSSION
Prospective randomized clinical trials have con-
firmed the efficacy of CEA over optimal medical man-
agement alone for the treatment of symptomatic6-8 and
asymptomatic9-10 patients with high-grade extracranial
carotid stenoses. However, CAS has emerged as an alter-
native treatment modality, especially in high-risk
patients. An endovascular approach may be better suited
for the treatment of patients with restenotic lesions after
CEA, with primary stenoses with high-risk medical
comorbidities, or with radiation-induced stenoses.
Although our group reported comparable results
between CAS and surgical management of post-CEA
restenoses,12 surgical intervention has generally been
associated with a higher rate of complications than those
reported after primary CEA. Bartlett et al22 reported a
30-day stroke and death rate of 6.0%, whereas Das et
al23 reported 4.6% and Treiman et al24 reported 3.5%.
All noted increased risks of transient cranial nerve
palsies. These results have stimulated interest in the use
of CAS for post-CEA restenoses.1,12,25,26
Coronary stenting has been associated with signifi-
cantly lower rates of angiographic and clinical restenosis
than angioplasty alone.27,28 This salutary effect may be
due to the stent’s ability to provide predictably larger arte-
rial lumens.29 However, myointimal hyperplasia accompa-
nies virtually every stent placement in the coronary, iliac,
or carotid system, and some patients have hyperplasia of
sufficient magnitude to cause flow-limiting restenosis.
Restenosis has been reported to be as high as 59% after
coronary angioplasty-stenting16 and 39% after iliac inter-
ventions.19 However, on the basis of collected clinical data
from 24 centers, Wholey et al21 reported a rate of resteno-
sis after CAS of only 4.8% (n = 2048) at a mean of 6
months of clinical follow-up. Diethrich et al3 defined a
restenosis rate of 4.5% after 8 months of follow-up,
whereas Yadav et al4 reported 4.9% at 6 months and
Theron20 reported 4% at 12 months. The basis for this
apparent lower incidence of in-stent restenosis in the
carotid circulation as compared with the coronary and iliac
vasculatures remains unknown. 
We investigated the incidence of in-stent restenosis
after CAS in a high-risk surgical group for a follow-up
interval of 18 ± 10 months (range, 1-44 months). We
observed four patients (8.7%) with significant (≥ 80%)
in-stent restenosis. Three of the patients were treated
with angioplasty alone (Fig 2), and the fourth patient
was treated with angioplasty and restenting. Although
our series of 50 CAS procedures has been restricted to
defined subgroups of patients,11 our cases of in-stent
restenosis have been observed in patients after prior
CEA or radiation therapy. Thus, our reported incidence
of in-stent restenosis may be more reflective of CAS per-
formed for post-CEA restenosis. Although myointimal
hyperplasia with smooth muscle cell proliferation is the
predominant mechanism leading to in-stent restenosis30
as well as the underlying mechanism for restenosis
occurring within 2 to 3 years of CEA,22-24 stent implan-
tation in a preexistent hyperplastic process may be asso-
ciated with a higher incidence of in-stent restenosis than
after CAS for primary stenosis.
Currently, we recommend CAS for post-CEA resteno-
sis, primary stenoses in high-risk patients, and radiation-
induced stenosis. The 30-day stroke and death rate in our
series was 2.2%. Although in-stent restenosis was detected
in four (8%) of the 50 CAS procedures, treatment with
angioplasty or angioplasty and re-stenting was effective
and not associated with neurologic complications. None
of these lesions has recurred during clinical or DU follow-
up. All patients continue to be asymptomatic, and no fur-
ther operative interventions have been performed in these
post-CAS patients.
Table III. Clinical characteristics of the patients with in-
stent restenosis (n = 4)
n %
Men 1 25
Women 3 75
Asymptomatic (> 80%) 4 100
Diabetes 1 25
Hypertension 2 50
Smoker 2 50
Hypercholesterolemia 1 25
Coronary artery disease 0 0
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DISCUSSION
Dr Timothy M. Sullivan (Greenville, SC). Since my time is
short and given Dr Porter’s previous comments, I’ll try and cut
to the chase. 
First, Dr Hobson, given the relatively benign nature of recur-
rent stenosis following carotid endarterectomy, there are those
who recommend treatment of these lesions only when they
become symptomatic. Given a combined risk of stroke and death
of 2.2% in your series, is it really reasonable to subject these
patients, the majority of whom did not have hemispheric symp-
toms, to an experimental and unproven therapy? Second, as a vas-
cular surgeon who performs carotid intervention, I’d like to know
when to consider operation for my patients with multiple recur-
rences and when to consider reintervention?
Third, the Wallstent has been shown to be a fairly efficient
machine for inducing myointimal hyperplasia in other arterial
beds, most notably the superficial femoral artery. Do you think
your results would be better if you had used a different stent, and
which stent are you currently using? 
Next, when considering interventional therapy for recurrent
stenoses following endarterectomy, do you differentiate between
early restenosis, which is likely myointimal and probably low risk
for intervention, and late restenosis, which is atherosclerotic and
may be higher risk for intervention? 
Finally, given the fairly low rate of restenosis that your group
and others have documented, and with the advent of cerebral
protection devices, the question that begs to be asked is, what are
your predictions for the fate of carotid endarterectomy over the
coming decade?
Although Dr Hobson has reported reasonable results for the
interventional treatment of carotid restenoses, it is important that
these results not be extrapolated to angioplasty for de novo carotid
stenoses. These are, however, important data. It is even more
important that vascular surgeons be involved in the review of this
new technology so that hard, peer-reviewed, and honest data are
utilized to dictate medical care for our patients, rather than reports
of anecdotal experiences from investigators who may have a per-
sonal and financial interest in the success of this new procedure. 
Thank you.
Dr Robert W. Hobson II. Thanks very much, Dr Sullivan.
Those are excellent questions.
First of all, we know that the restenotic lesion has a low neu-
rological event rate. However, data on restenoses ≥ 80% and their
possible progression to occlusion are not well defined. As a result,
we selected the 80% diameter-reducing stenosis as the threshold
for intervention. I recognize that this is controversial, and some
of you may not choose intervention in these cases. However, this
became part of our clinical protocol.
With regard to reoperations for restenosis, we have not found
that necessary during the last 4 years. Angioplasty and stenting
appear to be a reasonable alternative for initial cases of restenosis.
The Wallstent is not the stent of choice in my opinion. If you
remember the first case I presented with a focal restenosis, we used
a 40-mm stent, which resulted in a lengthy segment of normal
internal carotid being covered with the stainless steel stent.
Ultimately, if recurrent restenosis develops, operation with a venous
interposition graft may be required. However, we have not yet
encountered such a case. The newer nitinol technology will offer us
advantages in more precise placement of the stent and probably
with equivalent or perhaps even lower in-stent restenosis rates.
Early restenotic lesions due to myointimal hyperplasia (within
3 years of CEA) were selected preferentially in this series because
of an anticipated lower incidence of embolization during CAS.
For stenoses occurring beyond the 3-year interval, selection
would be based in part on the results of duplex ultrasonography.
For lesions comparable to primary atherosclerotic plaques, reop-
eration should be considered rather than CAS, until cerebral pro-
tection devices are available.
As far as our reported incidence of in-stent restenosis and the
ultimate decision about using this procedure in primary stenosis
patients, clearly, a need exists for randomized clinical trial
methodology. Our reported case series, performed over the last 4
years, accounted for less than 8% of our procedures in patients
with cerebrovascular insufficiency. Restenosis is an example of one
of the subsets of patients that the American Heart Association’s
Consensus Panel has suggested as reasonable for angioplasty and
stenting. But none of us will be prepared to move away from the
gold standard of carotid endarterectomy based on retrospective
evidence. Until we have data from randomized, prospective clin-
ical trials, endarterectomy will remain the mainstay of treatment
of patients with symptomatic and asymptomatic extracranial
carotid occlusive disease.
Thank you.
Dr. Kevin G. Burnand (London, United Kingdom). Dr
Hobson, thank you very much for that series.
Are you actually suggesting to us that the carotid is some sort
of privileged site in terms of the restenosis rate? Are you surprised
at the difference in restenosis rates from stents compared from the
angioplasty series that have been recorded?
Dr Hobson. I was surprised. Given the incidence of restenosis
after angioplasty-stenting in the coronary circulation and the iliac
arteries, many of my partners predicted that we’d be intervening on
in-stent restenosis cases by percutaneous techniques or perhaps
skull-based operations. However, our results have suggested a much
lower incidence of recurrent restenosis following CAS. As empha-
sized by Dr Sullivan, the earlier lesions are myointimal hyperplasia.
It is possible that the carotid artery’s high-flow rate and low cere-
brovascular resistance may result in an incidence of myointimal
hyperplasia that is lower than associated with other vasculatures.
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Dr William D. Turnipseed (Madison, Wis). We’re all aware of
the fact that whether you treat carotid stenosis by primary stent-
ing or carotid surgery, hyperplastic recurrence is a fact of life. My
concern is when there are tertiary and/or quartenary recurrences
that are often encountered, after re-endarterectomy and/or patch
placement with the same misery of recurrent stenosis thereafter.
It would seem at first blush that stenting would be an attractive
way to deal with this kind of recurrent lesion. From bad personal
experience, I would raise the question of whether there are rela-
tive contraindications for using stents in patients who have previ-
ous prosthetic patch placement for recurrent stenosis. We have
had two experiences, one in the iliac and one in the carotid artery,
where the patches disrupted late after the initial successful angio-
plasty. These became infected. Let me tell you, salvage procedures
for an infected mycotic aneurysm with a stent in place are very
challenging operations.
Dr Hobson. Bill, thank you for your comments. I’ll take your
word that it is a challenging operation.
However, with careful sizing of the stent, this is the pre-
ferred procedure for postendarterectomy restenosis. It is associ-
ated with a low complication rate. If in-stent restenosis does
occur, at least in our series, subsequent endovascular manage-
ment is an option that appears to be reasonable and safe. It
would also appear that the presence of a synthetic patch is not a
contraindication to the procedure.
Dr George Andros (Encino, Calif). I’m not going to com-
ment on the appropriateness of these procedures or the procedure
itself. And we scarcely need anybody else in the room to comment
on the controversies, as John is up there. But we certainly have to
take this as a landmark paper. To my recollection this is the first
paper that I know of in this Society—and it’s particularly appro-
priate that it’s given by the president-elect—in which all the
endoluminal procedures were done by a vascular surgeon. And I
think that signifies an end to when we’re going to see vascular
surgeons stand up here and present the work done by their inter-
ventional radiologists where they might not even have been in
town when the cases were done and they weren’t really sure what
kind of balloon was used in-stent. So I congratulate you, Bob. I
think that you’ve shown us the future, and it’s that vascular sur-
geons have to present their own endovascular work.
Dr Hobson. Thank you, George. We did collaborate with col-
leagues in cardiology. However, I scrubbed on every case, and our
fellow in vascular surgery has been an important part of this pro-
gram. I agree that it is time for vascular surgery to present its own
results on endovascular procedures.
Thank you very much.
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